cilomilast has been researched along with roflumilast in 39 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (roflumilast) | Trials (roflumilast) | Recent Studies (post-2010) (roflumilast) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 566 | 90 | 425 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Barlow, DJ; Ehrman, TM; Hylands, PJ | 1 |
| Huang, L; Jiang, HL; Lai, KF; Li, XS; Luo, ZH; Shan, WJ; Zhou, Q | 1 |
| Egerland, U; Gewald, R; Grunwald, C | 1 |
| Huang, L; Lai, K; Li, X; Shan, W; Xie, J; Zhou, Q | 1 |
| de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R | 1 |
| Chen, W; Dong, G; Feng, C; Gu, Z; Li, H; Li, J; Li, M; Liu, H; Tang, W; Xu, Y; Zhang, R; Zhang, X; Zhu, F | 1 |
| He, J; Ke, H; Peng, T; Qi, B; Shi, J | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| He, Y; Hou, R; Hou, S; Liao, C; Xie, Z; Yan, G | 1 |
| Fitzgerald, M; Sturton, G | 1 |
| Giembycz, MA | 1 |
| Draheim, R; Egerland, U; Rundfeldt, C | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Vignola, AM | 1 |
| Banner, KH; Trevethick, MA | 1 |
| Hanania, NA; Soto, FJ | 1 |
| Cortijo, J; Morcillo, EJ; Sanz, MJ | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Fan Chung, K | 1 |
| Abraham, WM; Claveau, D; Dias, R; Dubé, D; Gallant, M; Girard, Y; Goetghebeur, P; Huang, Z; Jones, T; Lacombe, P; Laliberte, F; Liu, S; Macdonald, D; Mancini, JA; Ng, K; Nicholson, DW; Otu, F; Styhler, A; Turner, MJ; Young, RN; Zhang, L | 1 |
| Chaves, J; Lerner, A; Makkinje, A; Meyers, JA; Taverna, J | 1 |
| Cui, X; Wang, D | 1 |
| Harada, D; Ikeda, Y; Kobayashi, K; Manabe, H; Nosaka, Y | 1 |
| Tatlicioğlu, T | 1 |
| Ball, D; Barnette, MS; Capper-Spudich, EA; Davis, TG; Ferrari, L; Knowles, RG; Kou, JP; Lucas, FS; Nials, AT; Peterson, JJ; Podolin, PL; Solanke, YE; Williamson, RA; Wiseman, J; Wren, P | 1 |
| Diamant, Z; Spina, D | 1 |
| Iwata, M; Kobayashi, M; Kubo, S; Ohtsu, Y; Shimizu, Y; Takahashi, K | 1 |
| Black, PN; Chong, J; Leung, B; Poole, P | 1 |
| Hirano, Y; Kobayashi, M; Kobayashi, S; Kubo, S; Shimizu, Y; Takahashi, K | 1 |
| Iwata, M; Kobayashi, M; Kubo, S; Miyata, K; Shimizu, Y; Takahashi, K | 1 |
| Krug, O; Schänzer, W; Thevis, M | 1 |
| Barg, M; Geerts, A; Quednau, R; Tersteegen, A; Wunder, F | 1 |
| Chong, J; Leung, B; Poole, P | 2 |
| Goto, T; Maeda, H; Nakamura, S; Suzuki, O; Yoshino, T | 1 |
| Fortescue, R; Janjua, S; Poole, P | 1 |
| Aguiar, JA; Ask, K; Cao, Q; Doxey, AC; Hirota, JA; Hou, V; Huff, RD; Inman, MD; Kim, Y; Miller, MS; Revill, S; Tiessen, N | 1 |
18 review(s) available for cilomilast and roflumilast
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Development; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Conformation; Quinolones; Vomiting | 2020 |
Zinc enzymes in medicinal chemistry.
Topics: Chemistry, Pharmaceutical; Enzyme Inhibitors; Enzymes; Humans; Models, Molecular; Zinc | 2021 |
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Carboxylic Acids; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Interactions; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
PDE4 inhibitors in COPD--a more selective approach to treatment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rolipram; Theophylline; Treatment Outcome | 2004 |
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Enzyme Inhibitors; Humans; Inflammatory Bowel Diseases; Nitriles | 2004 |
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Indoles; Inflammation; Lung; Nitriles; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2005 |
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Carboxylic Acids; Cell Adhesion Molecules; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2005 |
Phosphodiesterase inhibitors in airways disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Carboxylic Acids; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Isoenzymes; Nitriles; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2006 |
Evaluation of PDE4 inhibition for COPD.
Topics: Aminopyridines; Benzamides; Calcium Channel Blockers; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Circulation; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2006 |
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic AMP; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Topics: Aminopyridines; Benzamides; Clinical Trials, Phase III as Topic; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases, Obstructive; Nitriles; Phosphodiesterase 4 Inhibitors | 2011 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2011 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2013 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Diarrhea; Disease Progression; Forced Expiratory Volume; Humans; Middle Aged; Nitriles; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Vital Capacity | 2020 |
21 other study(ies) available for cilomilast and roflumilast
| Article | Year |
|---|---|
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2010 |
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Drug Design; Guinea Pigs; Inhibitory Concentration 50; Molecular Structure; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Trachea | 2012 |
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Topics: Administration, Oral; Animals; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 7; Drug Evaluation, Preclinical; Half-Life; Microsomes, Liver; Molecular Docking Simulation; Phosphodiesterase 4 Inhibitors; Protein Structure, Tertiary; Rats; Structure-Activity Relationship; Triazines | 2013 |
Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
Topics: Adrenergic beta-2 Receptor Agonists; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Design; Ethanolamines; Formoterol Fumarate; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Phthalazines; Receptors, Adrenergic, beta-2; Recombinant Proteins; Structure-Activity Relationship | 2014 |
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2016 |
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Topics: Animals; Caco-2 Cells; Catalytic Domain; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Male; Mice; Models, Molecular; Phosphodiesterase 4 Inhibitors; Psoriasis; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines; Tissue Distribution | 2019 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Cytokines; Humans; Indoles; Interleukin-2; Interleukin-4; Interleukin-5; Leukocytes, Mononuclear; Nitriles; Phosphodiesterase Inhibitors; Polyps; Tumor Necrosis Factor-alpha | 2004 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Apoenzymes; Ascaris suum; Asthma; Benzamides; Bronchoconstriction; Carboxylic Acids; Cognition Disorders; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Interferon-gamma; Male; Molecular Structure; Nitriles; Ovalbumin; Polymerase Chain Reaction; Quinolines; Rats; Sensitivity and Specificity; Sheep | 2007 |
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Apoptosis; Benzamides; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Dexamethasone; Gene Expression Regulation, Leukemic; Hematopoietic System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitriles; Phosphodiesterase Inhibitors; Receptors, Glucocorticoid; Rolipram | 2007 |
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Dermatitis; Dermatitis, Contact; Disease Models, Animal; Eosinophil Peroxidase; Interleukin-4; Male; Mice; Mice, Inbred BALB C; Nitriles; Peroxidase; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Picryl Chloride; Rolipram | 2008 |
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Ferrets; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pica; Piperazines; Pyridines; Rats; Rats, Inbred Lew; Receptors, Adrenergic, alpha-2; Rolipram; Tumor Necrosis Factor-alpha; Vomiting | 2009 |
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Aminopyridines; Animals; Benzamides; Blood Cells; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Enzyme Inhibitors; Ferrets; Interleukin-4; Lipopolysaccharides; Macrophages, Alveolar; Naphthyridines; Nitriles; Pneumonia; Rats; Tumor Necrosis Factor-alpha; Vomiting | 2011 |
Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Benzamides; Bronchial Hyperreactivity; Bronchoconstriction; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Eosinophils; Female; Guinea Pigs; In Vitro Techniques; Lung; Male; Naphthyridines; Nitriles; Ovalbumin; Phosphodiesterase 4 Inhibitors; Rats; Trachea | 2012 |
Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Topics: Adult; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage Fluid; Cells, Cultured; Chemokine CXCL1; Cyclohexanecarboxylic Acids; Cyclopropanes; Glucocorticoids; Humans; Lipopolysaccharides; Male; Naphthyridines; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Pneumonia; Prednisolone; Rats; Rats, Wistar; Superoxides; Tumor Necrosis Factor-alpha | 2012 |
Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
Topics: Aminopyridines; Benzamides; Chromatography, Liquid; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Limit of Detection; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry | 2013 |
Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
Topics: Aminopyridines; Animals; Benzamides; CHO Cells; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide-Gated Cation Channels; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Models, Biological; Nitriles; Phosphodiesterase 4 Inhibitors; Pyridines; Receptors, Adrenergic, beta-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor.
Topics: Adult; Aminopyridines; Benzamides; Chemotaxis; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Dose-Response Relationship, Drug; Female; Humans; Interleukin-8; Leukocytes, Mononuclear; Leukotriene B4; Lipopolysaccharides; Male; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
Potentiation of long-acting β
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Benzothiazoles; Budesonide; Cell Line; Chemokines; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Formoterol Fumarate; Glucocorticoids; Humans; Lung; Multidrug Resistance-Associated Proteins; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Second Messenger Systems; Triazoles | 2021 |